Next-generation sequencing reveals new insights about gene usage and CDR-H3 composition in the horse antibody repertoire.

The research article investigates the diverse genetic components constituting horse serum antibodies using next-generation sequencing technology. The study further explores the unique characteristic patterns if any, of the horse antibody structure and offers insights for future therapeutic applications.

Next-Generation Sequencing for Antibody Analysis

• The study harnesses next-generation sequencing (NGS) for a comprehensive review of the equine B-cell repertoire. This sophisticated technology facilitates an efficient, in-depth investigation of the genetic makeup of antibodies at a granular level.
• Through NGS, the researchers were able to identify almost 45,000 clonotypes for the heavy-chain (IGH) and roughly 30,000 clonotypes for the lambda light-chain (IGL) loci, painting a detailed picture of the antibody diversity.

Discovery of Common and Rare Gene Usage

• The study found a skewed use of the commonly employed subgroups IGHV2 (92.49%) and IGLV8 (82.50%). These observations are consistent with previous reports, indicating a preference for certain genomic segments in antibody production.
• Importantly, the researchers also uncovered the usage of the less frequent genes, IGHV6S1 and IGLV4S2. This finding highlights the continual adaptation and versatility of the horse’s immune system in generating antibodies.

Insight into CDR-H3 Amino Acid Composition

• A specific area of investigation in this study was the Complementarity-Determining Region 3 (CDR-H3), a crucial component of an antibody due to its role in antigen recognition.
• The researchers noticed unique amino acid patterns at positions 106 and 116 when compared with humans, rabbits, and mice. This suggests that an extended conformation predominantly characterizes horse CDR-H3 loops, which differentiate them from other species.

Relevance for Synthetic Antibody Design

• The knowledge gained from this exploration offers valuable insights for the medical community. An improved understanding of the structural and composition particularities of horse antibodies could guide the design of synthetic antibodies for future therapeutic use, such as in treating and preventing infectious diseases and venomous bites.
• The uncovering of both the common and infrequently used genes could pave the way for the creation of genetically-engineered antibodies with specific efficiencies in mind.